• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

城市社区卫生中心双膦酸盐治疗方案偏好调查。

Survey of bisphosphonate regimen preferences in an urban community health center.

作者信息

Ryzner Kristi L, Burkiewicz Jill S, Griffin Brooke L, Komperda Kathy E

机构信息

Department of Pharmacy, Boston Medical Center, Boston, Massachusetts, USA.

出版信息

Consult Pharm. 2010 Oct;25(10):671-5. doi: 10.4140/TCP.n.2010.671.

DOI:10.4140/TCP.n.2010.671
PMID:21030357
Abstract

OBJECTIVE

to determine patient preference for bisphosphonate therapy based on dosage form and dosing schedule.

DESIGN

prospective telephone survey.

SETTING

urban community health center.

PATIENTS, PARTICIPANTS: all patients who were seen in the osteoporosis clinic during the 22-month time period were contacted. Patients were excluded if they could not complete the survey in English, had difficulty hearing, had cognitive impairment, or were unable to be reached by telephone.

INTERVENTIONS

patients were asked which route and frequency of bisphosphonate therapy was preferred, convenient, and easiest to remember.

MAIN OUTCOME MEASURE(S): patient-reported preference for route and frequency of bisphosphonate administration.

RESULTS

ninety patients were included in the final analysis. Preference for bisphosphonate therapy illustrated that equal numbers of respondents preferred either once-monthly or once-yearly regimens (24.4% for each, n = 22). One-third of respondents (n = 30) indicated that a once-yearly infusion was the most convenient method of administration. The survey revealed no strong association of which regimen was easiest to remember.

CONCLUSION

the majority of patients preferred once-monthly or less frequent dosing schedules. Clinicians may consider discussing patient preferences during initiation and throughout therapy.

摘要

目的

根据剂型和给药方案确定患者对双膦酸盐治疗的偏好。

设计

前瞻性电话调查。

地点

城市社区卫生中心。

患者、参与者:联系了在22个月期间骨质疏松门诊就诊的所有患者。如果患者无法用英语完成调查、听力有困难、有认知障碍或无法通过电话联系到,则将其排除。

干预措施

询问患者双膦酸盐治疗的哪种途径和频率是首选的、方便的且最容易记住的。

主要观察指标

患者报告的双膦酸盐给药途径和频率的偏好。

结果

90名患者纳入最终分析。双膦酸盐治疗的偏好表明,选择每月一次或每年一次治疗方案的受访者人数相等(各占24.4%,n = 22)。三分之一的受访者(n = 30)表示每年一次静脉输注是最方便的给药方法。调查显示,对于哪种治疗方案最容易记住,没有强烈的关联。

结论

大多数患者更喜欢每月一次或更低频率的给药方案。临床医生在开始治疗和整个治疗过程中可考虑讨论患者的偏好。

相似文献

1
Survey of bisphosphonate regimen preferences in an urban community health center.城市社区卫生中心双膦酸盐治疗方案偏好调查。
Consult Pharm. 2010 Oct;25(10):671-5. doi: 10.4140/TCP.n.2010.671.
2
[Further characterization between oral bisphosphonate dosing interval and patient preference--patient preference for daily, weekly and monthly bisphosphonate, based on results of 3,052 outpatients questionnaires].[口服双膦酸盐给药间隔与患者偏好之间的进一步特征分析——基于3052份门诊患者问卷结果的患者对每日、每周和每月双膦酸盐的偏好]
Nihon Rinsho. 2013 Dec;71(12):2223-31.
3
Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.接受双膦酸盐治疗患者的偏好——如何影响治疗依从性。
Biomed Pharmacother. 2008 Feb;62(2):122-4. doi: 10.1016/j.biopha.2007.07.005. Epub 2007 Aug 9.
4
Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.新型双膦酸盐给药方案在骨质疏松症中的临床评估:比较研究的作用及对未来研究的启示
Clin Ther. 2007 Jun;29(6):1116-27. doi: 10.1016/j.clinthera.2007.06.009.
5
Is there an advantage to an injected bisphosphonate versus a daily or monthly oral regimen?注射用双膦酸盐相对于每日或每月口服方案有优势吗?
Mayo Clin Womens Healthsource. 2008 Sep;12(9):8.
6
Improving compliance and persistence with bisphosphonate therapy for osteoporosis.提高骨质疏松症双膦酸盐治疗的依从性和持续性。
Am J Med. 2006 Apr;119(4 Suppl 1):S18-24. doi: 10.1016/j.amjmed.2005.12.019.
7
[Bisphosphonate therapy for osteoporosis and bone strength].[双膦酸盐治疗骨质疏松症与骨强度]
Clin Calcium. 2006 Sep;16(9):1513-19.
8
Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.每年静脉注射一次唑来膦酸用于治疗绝经后骨质疏松症。
Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.
9
Question: In postmenopausal women with osteoporosis is once monthly oral ibandronate (150 mg) therapy preferred to once weekly oral bisphosphonate therapy.
J Okla State Med Assoc. 2012 Mar;105(3):89-90.
10
The oral health status of patients on oral bisphosphonates for osteoporosis.使用口服双膦酸盐治疗骨质疏松症患者的口腔健康状况。
Aust Dent J. 2008 Dec;53(4):354-7; quiz 366. doi: 10.1111/j.1834-7819.2008.00078.x.

引用本文的文献

1
Current situation of shared decision making in osteoporosis: A comprehensive literature review of patient decision aids and decision drivers.骨质疏松症共同决策的现状:患者决策辅助工具和决策驱动因素的综合文献综述
Health Sci Rep. 2022 Nov 21;5(6):e849. doi: 10.1002/hsr2.849. eCollection 2022 Nov.
2
Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ).评估罕见病治疗的偏好:阵发性夜间血红蛋白尿患者偏好问卷(PNH-PPQ)的定性开发
Patient Prefer Adherence. 2020 Apr 5;14:705-715. doi: 10.2147/PPA.S233830. eCollection 2020.
3
Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates.
静脉注射唑来膦酸与其他双膦酸盐相比在骨质疏松症治疗中的依从性和偏好性
Eur J Hosp Pharm. 2019 Jan;26(1):4-9. doi: 10.1136/ejhpharm-2017-001258. Epub 2017 Sep 20.
4
Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.用于乳腺癌和前列腺癌骨转移的骨靶向药物使用情况:一项患者调查。
J Bone Oncol. 2013 Jun 21;2(3):105-9. doi: 10.1016/j.jbo.2013.05.002. eCollection 2013 Sep.
5
Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.在医疗保险优势处方药计划中,骨质疏松症治疗改变与依从性、骨折事件和总医疗保健成本之间的关系。
Osteoporos Int. 2013 Apr;24(4):1195-206. doi: 10.1007/s00198-012-2140-5. Epub 2012 Oct 26.